EMEA-003591-PIP01-24

Opinion/decision on a Paediatric investigation plan (PIP): Kisqali, Ribociclib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neoplasms benign, malignant and unspecified (incl cysts and polyps), PIP number: P/0266/2024

Opinion/decision on a Paediatric investigation plan (PIP): Jemperli, dostarlimab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Neoplasms benign, malignant and unspecified (incl cysts and polyps), PIP number: P/0260/2024

Opinion/decision on a Paediatric investigation plan (PIP): Briumvi, Ublituximab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Nervous system disorders, PIP number: P/0254/2024

EMEA-003302-PIP01-22-M01

EMEA-000835-PIP01-10-M01

EMEA-003260-PIP03-23

Article 57 product data

EMEA-002338-PIP05-23

Human medicines European public assessment report (EPAR): Orgovyx, relugolix, Date of authorisation: 29/04/2022, Revision: 12, Status: Authorised